Importance: The limited data on cancer phenotypes in men with germline BRCA1 and BRCA2 pathogenic variants (PVs) have hampered the development of evidence-based recommendations for early cancer detection and risk reduction in this population. Objective: To compare the cancer spectrum and frequencies between male BRCA1 and BRCA2 PV carriers. Design, setting, and participants: Retrospective cohort study of 6902 men, including 3651 BRCA1 and 3251 BRCA2 PV carriers, older than 18 years recruited from cancer genetics clinics from 1966 to 2017 by 53 study groups in 33 countries worldwide collaborating through the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Clinical data and pathologic characteristics were collected. Main outcomes and measures: BRCA1/2 status was the outcome in a logistic regression, and cancer diagnoses were the independent predictors. All odds ratios (ORs) were adjusted for age, country of origin, and calendar year of the first interview. Results: Among the 6902 men in the study (median [range] age, 51.6 [18-100] years), 1634 cancers were diagnosed in 1376 men (19.9%), the majority (922 of 1,376 [67%]) being BRCA2 PV carriers. Being affected by any cancer was associated with a higher probability of being a BRCA2, rather than a BRCA1, PV carrier (OR, 3.23; 95% CI, 2.81-3.70; P < .001), as well as developing 2 (OR, 7.97; 95% CI, 5.47-11.60; P < .001) and 3 (OR, 19.60; 95% CI, 4.64-82.89; P < .001) primary tumors. A higher frequency of breast (OR, 5.47; 95% CI, 4.06-7.37; P < .001) and prostate (OR, 1.39; 95% CI, 1.09-1.78; P = .008) cancers was associated with a higher probability of being a BRCA2 PV carrier. Among cancers other than breast and prostate, pancreatic cancer was associated with a higher probability (OR, 3.00; 95% CI, 1.55-5.81; P = .001) and colorectal cancer with a lower probability (OR, 0.47; 95% CI, 0.29-0.78; P = .003) of being a BRCA2 PV carrier. Conclusions and relevance: Significant differences in the cancer spectrum were observed in male BRCA2, compared with BRCA1, PV carriers. These data may inform future recommendations for surveillance of BRCA1/2-associated cancers and guide future prospective studies for estimating cancer risks in men with BRCA1/2 PVs.
Characterization of the cancer spectrum in men with germline BRCA1 and BRCA2 pathogenic variants / Silvestri, Valentina; Leslie, Goska; Barnes, Daniel R.; Agnarsson, Bjarni A.; Aittomäki, Kristiina; Alducci, Elisa; Andrulis, Irene L.; Barkardottir, Rosa B.; Barroso, Alicia; Barrowdale, Daniel; Benitez, Javier; Bonanni, Bernardo; Borg, Ake; Buys, Saundra S.; Caldés, Trinidad; Caligo, Maria A.; Capalbo, Carlo; Campbell, Ian; Chung, Wendy K.; Claes, Kathleen B. M.; Colonna, Sarah V.; Cortesi, Laura; Couch, Fergus J.; de la Hoya, Miguel; Diez, Orland; Ding, Yuan Chun; Domchek, Susan; Easton, Douglas F.; Ejlertsen, Bent; Engel, Christoph; Evans, D. Gareth; Feliubadalò, Lidia; Foretova, Lenka; Fostira, Florentia; Géczi, Lajos; Gerdes, Anne-Marie; Glendon, Gord; Godwin, Andrew K.; Goldgar, David E.; Hahnen, Eric; Hogervorst, Frans B. L.; Hopper, John L.; Hulick, Peter J.; Isaacs, Claudine; Izquierdo, Angel; James, Paul A.; Janavicius, Ramunas; Jensen, Uffe Birk; John, Esther M.; Joseph, Vijai; Konstantopoulou, Irene; Kurian, Allison W.; Kwong, Ava; Landucci, Elisabetta; Lesueur, Fabienne; Loud, Jennifer T.; Machackova, Eva; Mai, Phuong L.; Majidzadeh-A, Keivan; Manoukian, Siranoush; Montagna, Marco; Moserle, Lidia; Mulligan, Anna Marie; Nathanson, Katherine L.; Nevanlinna, Heli; Ngeow Yuen Ye, Joanne; Nikitina-Zake, Liene; Offit, Kenneth; Olah, Edith; Olopade, Olufunmilayo I.; Osorio, Ana; Papi, Laura; Park, Sue K.; Pedersen, Inge Sokilde; Perez-Segura, Pedro; Petersen, Annabeth H.; Pinto, Pedro; Porfirio, Berardino; Pujana, Miquel Angel; Radice, Paolo; Rantala, Johanna; Rashid, Muhammad U.; Rosenzweig, Barak; Rossing, Maria; Santamariña, Marta; Schmutzler, Rita K.; Senter, Leigha; Simard, Jacques; Singer, Christian F.; Solano, Angela R.; Southey, Melissa C.; Steele, Linda; Steinsnyder, Zoe; Stoppa-Lyonnet, Dominique; Tan, Yen Yen; Teixeira, Manuel R.; Teo, Soo H.; Terry, Mary Beth; Thomassen, Mads; Toland, Amanda E.; Torres-Esquius, Sara; Tung, Nadine; van Asperen, Christi J.; Vega, Ana; Viel, Alessandra; Vierstraete, Jeroen; Wappenschmidt, Barbara; Weitzel, Jeffrey N.; Wieme, Greet; Yoon, Sook-Yee; Zorn, Kristin K.; Mcguffog, Lesley; Parsons, Michael T.; Hamann, Ute; Greene, Mark H.; Kirk, Judy A.; Neuhausen, Susan L.; Rebbeck, Timothy R.; Tischkowitz, Marc; Chenevix-Trench, Georgia; Antoniou, Antonis C.; Friedman, Eitan; Ottini, Laura. - In: JAMA ONCOLOGY. - ISSN 2374-2437. - 6:8(2020), pp. 1218-1230. [10.1001/jamaoncol.2020.2134]
Characterization of the cancer spectrum in men with germline BRCA1 and BRCA2 pathogenic variants
Silvestri, ValentinaPrimo
;Capalbo, CarloMembro del Collaboration Group
;Ottini, Laura
Membro del Collaboration Group
2020
Abstract
Importance: The limited data on cancer phenotypes in men with germline BRCA1 and BRCA2 pathogenic variants (PVs) have hampered the development of evidence-based recommendations for early cancer detection and risk reduction in this population. Objective: To compare the cancer spectrum and frequencies between male BRCA1 and BRCA2 PV carriers. Design, setting, and participants: Retrospective cohort study of 6902 men, including 3651 BRCA1 and 3251 BRCA2 PV carriers, older than 18 years recruited from cancer genetics clinics from 1966 to 2017 by 53 study groups in 33 countries worldwide collaborating through the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Clinical data and pathologic characteristics were collected. Main outcomes and measures: BRCA1/2 status was the outcome in a logistic regression, and cancer diagnoses were the independent predictors. All odds ratios (ORs) were adjusted for age, country of origin, and calendar year of the first interview. Results: Among the 6902 men in the study (median [range] age, 51.6 [18-100] years), 1634 cancers were diagnosed in 1376 men (19.9%), the majority (922 of 1,376 [67%]) being BRCA2 PV carriers. Being affected by any cancer was associated with a higher probability of being a BRCA2, rather than a BRCA1, PV carrier (OR, 3.23; 95% CI, 2.81-3.70; P < .001), as well as developing 2 (OR, 7.97; 95% CI, 5.47-11.60; P < .001) and 3 (OR, 19.60; 95% CI, 4.64-82.89; P < .001) primary tumors. A higher frequency of breast (OR, 5.47; 95% CI, 4.06-7.37; P < .001) and prostate (OR, 1.39; 95% CI, 1.09-1.78; P = .008) cancers was associated with a higher probability of being a BRCA2 PV carrier. Among cancers other than breast and prostate, pancreatic cancer was associated with a higher probability (OR, 3.00; 95% CI, 1.55-5.81; P = .001) and colorectal cancer with a lower probability (OR, 0.47; 95% CI, 0.29-0.78; P = .003) of being a BRCA2 PV carrier. Conclusions and relevance: Significant differences in the cancer spectrum were observed in male BRCA2, compared with BRCA1, PV carriers. These data may inform future recommendations for surveillance of BRCA1/2-associated cancers and guide future prospective studies for estimating cancer risks in men with BRCA1/2 PVs.| File | Dimensione | Formato | |
|---|---|---|---|
|
Silvestri_Cancer-spectrum_2020.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
350.26 kB
Formato
Adobe PDF
|
350.26 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
